GPER G-1 is a drug discovery and development company with the primary goal of advancing pre-clinical development of novel drug candidates that modulate the G-Protein Coupled Estrogen Receptor (GPER). The lead drug candidate is G-1 (EsperaTM), which is a GPER agonist to treat obesity through weight loss, and to reverse diabetes and pre-diabetes.